NASDAQ:TPIV
Delisted

TapImmune Inc Fund Company Profile

$8.34
+0 (+0%)
At Close: Oct 26, 2018

Information

50 North Laura Street

Jacksonville FL 32202

904-516-5436

Description

TapImmune, Inc., a clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The company, in collaboration with Mayo Foundation for Medical Education and Research, is developing HER2/neu+, a vaccine technology, which has completed Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which has completed Phase I clinical trials for the treatment of breast and ovarian cancer. Its products under preclinical stage include Polystart, a nucleic acid-based technology for HER2/neu+ breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. The company was founded in 1999 and is headquartered in Jacksonville, Florida.

Click to get the best stock tips daily for free!